ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "abatacept and patient-reported outcome measures"

  • Abstract Number: 2748 • 2015 ACR/ARHP Annual Meeting

    Evaluation of Patient-Reported Outcomes By Baseline Disease Duration: 6-Month Data from Two Clinical Trials of Patients with Early Rheumatoid Arthritis Treated with Abatacept

    Daniel E. Furst1, VP Bykerk2, Gerd Burmester3, BG Combe4, T. W. J. Huizinga5, E Alemao6, A Johnsen6 and Paul Emery7, 1Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Weill Cornell Medical College, New York, NY, 3Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, 4Montpellier University, Montpellier, France, 5Leiden University Medical Center, Leiden, Netherlands, 6Bristol-Myers Squibb, Princeton, NJ, 7University of Leeds, Leeds, United Kingdom

    Background/Purpose: Patients with RA and longer disease duration generally do not respond as well to treatment with DMARDs as patients with shorter duration of disease.…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.